
BMEA
Biomea Fusion Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.810
Open
1.800
VWAP
--
Vol
890.07K
Mkt Cap
94.09M
Low
1.650
Amount
--
EV/EBITDA(TTM)
--
Total Shares
35.94M
EV
56.11M
EV/OCF(TTM)
--
P/S(TTM)
--
Biomea Fusion, Inc. is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company has built its proprietary FUSION System discovery platform to advance a pipeline of small molecule product candidates. Its lead clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, and selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. Its second product candidate BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1 RA), for the treatment of diabetes and obesity.
Show More
6 Analyst Rating

536.36% Upside
Wall Street analysts forecast BMEA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMEA is 10.50 USD with a low forecast of 3.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy

536.36% Upside
Current: 1.650

Low
3.00
Averages
10.50
High
30.00

536.36% Upside
Current: 1.650

Low
3.00
Averages
10.50
High
30.00
Citi
Buy
downgrade
$22 -> $9
2025-07-16
Reason
Citi
Price Target
$22 -> $9
2025-07-16
downgrade
Buy
Reason
Citi lowered the firm's price target on Biomea Fusion to $9 from $22 and keeps a Buy rating on the shares. The firm cites the company's strategic realignment for the target cut. With the focus now metabolic disease, Biomea is no longer pursuing oncology, the analyst tells investors in a research note.
H.C. Wainwright
Joseph Pantginis
Buy
downgrade
$18 -> $4
2025-06-23
Reason
H.C. Wainwright
Joseph Pantginis
Price Target
$18 -> $4
2025-06-23
downgrade
Buy
Reason
H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Biomea Fusion to $4 from $18 and keeps a Buy rating on the shares, citing the June fundraising with "significant dilution" for the firm's revised target. At the ADA meeting, Biomea presented additional preclinical data highlighting icovamenib's potential for combination therapies, notes the analyst, who contends that icovamenib "stands out" for combination approaches and lean mass preservation.
Piper Sandler
Edward Tenthoff
Overweight
initiated
$7
2025-06-02
Reason
Piper Sandler
Edward Tenthoff
Price Target
$7
2025-06-02
initiated
Overweight
Reason
Piper Sandler analyst Edward Tenthoff assumedcoverage of Biomea Fusion with an Overweight rating and $7 price target. The company is developing icovamenib to treat diabetes, a covalent menin inhibitor, the analyst tells investors in a research note. Piper views Biomea as an emerging diabetes and obesity play.
Barclays
Peter Lawson
Hold
Maintains
$11 → $3
2025-04-02
Reason
Barclays
Peter Lawson
Price Target
$11 → $3
2025-04-02
Maintains
Hold
Reason
Barclays lowered the firm's price target on Biomea Fusion to $3 from $11 and keeps an Equal Weight rating on the shares following the Q4 report. The company's catalysts are on track with a focus around a path forward for icovamenib, the analyst tells investors in a research note.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$40
2025-04-01
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$40
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$40
2025-03-31
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$40
2025-03-31
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Biomea Fusion Inc (BMEA.O) is -1.19, compared to its 5-year average forward P/E of -3.93. For a more detailed relative valuation and DCF analysis to assess Biomea Fusion Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-3.93
Current PE
-1.19
Overvalued PE
-1.02
Undervalued PE
-6.84
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-2.49
Current EV/EBITDA
-0.73
Overvalued EV/EBITDA
2.09
Undervalued EV/EBITDA
-7.06
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
-27.64%
-29.71M
Operating Profit
FY2025Q1
YoY :
-25.09%
-29.26M
Net Income after Tax
FY2025Q1
YoY :
-26.61%
-0.80
EPS - Diluted
FY2025Q1
YoY :
-19.95%
-25.67M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
100.6K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
657.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
100.6K
USD
Months
BMEA News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
07:12:01
Biomea Fusion appoints Julianne Averill to board of directors

2025-06-23 (ET)
2025-06-23
07:30:38
Biomea Fusion announces presentation of icovamenib preclinical, clinical data

2025-06-20 (ET)
2025-06-20
08:45:01
Largest borrow rate increases among liquid names

Sign Up For More Events
Sign Up For More Events
News
5.0
07-24NewsfilterBiomea Fusion Appoints Julianne Averill to its Board of Directors
4.5
06-18BenzingaCrude Oil Moves Higher; US Weekly Jobless Claims Decline
9.0
06-18NewsfilterBiomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates
Sign Up For More News
People Also Watch

MPAA
Motorcar Parts of America Inc
11.700
USD
-2.82%

INMB
INmune Bio Inc
3.160
USD
+8.59%

VTYX
Ventyx Biosciences Inc
2.670
USD
-12.17%

KYTX
Kyverna Therapeutics Inc
3.850
USD
-11.09%

SGHT
Sight Sciences Inc
3.460
USD
-2.26%

ZJYL
Jin Medical International Ltd
0.640
USD
-3.17%

NBTX
Nanobiotix SA
6.948
USD
+4.56%

MDV
Modiv Industrial Inc
14.640
USD
+0.90%

RMBI
Richmond Mutual Bancorporation Inc
14.470
USD
+1.62%

FRGE
Forge Global Holdings Inc
16.670
USD
-3.86%
FAQ

What is Biomea Fusion Inc (BMEA) stock price today?
The current price of BMEA is 1.65 USD — it has decreased -8.33 % in the last trading day.

What is Biomea Fusion Inc (BMEA)'s business?

What is the price predicton of BMEA Stock?

What is Biomea Fusion Inc (BMEA)'s revenue for the last quarter?

What is Biomea Fusion Inc (BMEA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Biomea Fusion Inc (BMEA)'s fundamentals?

How many employees does Biomea Fusion Inc (BMEA). have?
